The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Onyia Jude since 2022.
This trader's CIK number is 1894425.
At the time of last reporting, Onyia Jude was the Chief Scientific Officer of Neurocrine Biosciences Inc. (stock ticker symbol NBIX).
Also see all insider trading activities at Neurocrine Biosciences Inc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | NBIX | 0 | $0 | 83,186 | $10,808,945 | 85,826 | $6,794,537 |
| 2024 | NBIX | 0 | $0 | 3,889 | $502,627 | 4,426 | $0 |
| 2023 | NBIX | 0 | $0 | 10,163 | $1,082,939 | 0 | $0 |
| 2022 | NBIX | 0 | $0 | 2,331 | $284,160 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-07-09 | NBIX | Sale | 59,819 | 130.46 | 7,803,687 |
| 2025-07-09 | NBIX | Option Ex | 59,819 | 84.74 | 5,069,062 |
| 2025-07-02 | NBIX | Option Ex | 20,362 | 84.74 | 1,725,475 |
| 2025-07-02 | NBIX | Sale | 20,362 | 130.13 | 2,649,747 |
| 2025-02-13 | NBIX | Option Ex | 5,407 | .00 | 0 |
| 2025-02-13 | NBIX | Sale | 2,879 | 116.79 | 336,238 |
| 2025-01-31 | NBIX | Sale | 126 | 152.97 | 19,273 |
| 2025-01-31 | NBIX | Option Ex | 238 | .00 | 0 |
| 2024-11-29 | NBIX | Option Ex | 4,426 | .00 | 0 |
| 2024-11-29 | NBIX | Sale | 2,331 | 126.29 | 294,372 |
| 2024-02-13 | NBIX | Sale | 1,432 | 132.94 | 190,371 |
| 2024-01-31 | NBIX | Sale | 126 | 141.94 | 17,884 |
| 2023-11-29 | NBIX | Sale | 2,331 | 113.57 | 264,734 |
| 2023-08-21 | NBIX | Sale | 3,198 | 107.37 | 343,369 |
| 2023-02-07 | NBIX | Sale | 4,508 | 102.30 | 461,168 |
| 2023-01-31 | NBIX | Sale | 126 | 108.48 | 13,668 |
| 2022-11-29 | NBIX | Sale | 2,331 | 121.91 | 284,160 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Onyia Jude (Chief Scientific Officer of Neurocrine Biosciences Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.